FORCE's eXamining the Relevance of Articles for You (XRAY) program looks behind the headlines of cancer news to help you understand what the research means for you.
XRAY is a reliable source of hereditary cancer research-related news and information.
Learn more about the XRAY program
All XRAYs
Relevance: Medium-High
Strength of Science: High
Research Timeline: Human Research
Study : Promising early results for treating metastatic prostate cancer
Relevance: Medium-High
Strength of Science: High
Research Timeline: Human Research
Most relevant for: People with metastatic castration-resistant prostate cancer (mCRPC)
The TALAPRO studies looked at how well the oral drug Talzenna (talazoparib) works as a treatment for metastatic castration-resistant prostate cancer (mCRPC). The addition of Talzenna to treatment with Xtandi (enzalutamide) increased the time until the cancer got worse or came back (progression-free survival). The greatest benefit was seen in people who had an inherited or tumor mutation in a gene that repairs DNA damage (such as ATM, BRCA1, BRCA2 and others). (Posted 3/1/23)
Update: On June 20, 2023, the Food and Drug Administration (FDA) approved the combination of Talzenna with Xtandi as an initial treatment for some people with mCRPC for people with inherited or tumor mutations in genes that repair DNA damage.
Este artículo está disponible en español.
Read More
Relevance: High
Strength of Science: High
Study : Treatment to reduce bone fractures also improves breast cancer survival in postmenopausal people
Relevance: High
Strength of Science: High
Most relevant for: People with early-stage breast cancer who are post-menopausal
A large study looked at the effects of adding the bone-protective drug denosumab (Prolia), to standard hormone therapy for the treatment of early-stage, postmenopausal, HR-positive breast cancer. The researchers found that adding denosumab to aromatase inhibitor hormonal therapy improved bone health, disease-free survival and overall survival. (Posted 2/27/23)
Este artículo está disponible en español.
Read More
Study : Increasing soy in your diet may lower your cancer risk
Most relevant for: People interested in reducing cancer risk
This study looked at a link between a diet rich in soy and cancer risk. With the addition of more recent literature, this study suggests that soy lowers the risk of cancer in the general population. (Posted 2/24/23)
Este artículo está disponible en español.
Read More
Relevance: Medium
Strength of Science: Medium-High
Research Timeline: Post Approval
Study : Frequent aspirin use may reduce the risk of ovarian cancer
Relevance: Medium
Strength of Science: Medium-High
Research Timeline: Post Approval
Most relevant for: Healthy people at high-risk of ovarian cancer.
Aspirin may help lower the risk of ovarian cancer in people who have a high risk of the disease, according to a new analysis of 17 studies. While other preventive strategies have been found to more effectively lower the likelihood of developing ovarian cancer in high-risk women, taking aspirin daily or almost daily may reduce a person’s risk of developing ovarian cancer by 13 percent. The benefit was greater among people with additional risk factors for the disease. (Posted 2/22/23)
Este artículo está disponible en español.
Read More
Relevance: Medium-High
Strength of Science: High
Research Timeline: Post Approval
Study : Trodelvy benefits people with advanced hormone-positive metastatic breast cancer
Relevance: Medium-High
Strength of Science: High
Research Timeline: Post Approval
Most relevant for: People with ER/PR-positive, HER2-negative metastatic breast cancer
The study TROPiCS-2 showed that the drug Trodelvy (sacituzumab govitecan) improved progression-free survival when compared to chemotherapy in people with advanced metastatic ER/PR-positive, HER2-negative breast cancer who have few other treatment options. This drug does not yet have FDA approval for use in the hormone-positive setting. (Posted 1/18/23)
Update: On 02/03/2023 the FDA approved Trodelvy for patients with locally advanced or metastatic breast cancer who have received hormonal therapy and at least two other types of treatment in the metastatic setting.
Este artículo está disponible en español.
Read More
Update : Breast cancer vaccine trial begins enrolling people with BRCA1 and PALB2 mutations
Most relevant for: People with a BRCA1 or PALB2 mutation undergoing prophylactic bilateral mastectomy
A new vaccine was first tested on people diagnosed with triple-negative breast cancer. The vaccine is now being tested to prevent breast cancer among people with an inherited mutation in BRCA1 or PALB2 who are at high risk and who are planning to have a risk-reducing mastectomy. (Posted 1/9/23) Este artículo está disponible en español.
Read More
Relevance: High
Strength of Science: High
Study : What influences aggressive end-of-life care for ovarian cancer?
Relevance: High
Strength of Science: High
Most relevant for: People with advanced ovarian cancer
Aggressive medical treatment is often given to people with terminal ovarian cancer when prior treatment has stopped working. This aggressive end-of-life treatment conflicts with clinical guidelines, may increase pain and suffering and does not extend life. This study found that the end-of-life care that a person with ovarian cancer receives is influenced by their doctors. (Posted 1/3/23)
Este artículo está disponible en español.
Read More
Relevance: Medium-High
Strength of Science: Medium-High
Research Timeline: Human Research
Study : Male breast cancer: Patient and surgeon experiences
Relevance: Medium-High
Strength of Science: Medium-High
Research Timeline: Human Research
Most relevant for: Men with breast cancer
By surveying male breast cancer patients and the surgeons who treat them, researchers gained insight into the experiences of both groups, shedding light on an important issue for men with breast cancer. (Posted 12/22/22)
Este artículo está disponible en español.
Read More
Topic : Cancer disparities in American Indian and Alaska Native populations
Most relevant for: Americans Indians and Alaska Natives
The American Cancer Society released a special section in their 2022 Cancer Facts & Figures report that discussed cancer disparities in American Indian and Alaska Native populations in the United States. This review highlights the special section’s main points, including disparities in cancer screening, diagnosis and survival rates in native communities, as well as factors contributing to those disparities. (Posted 12/20/22)
Este artículo está disponible en español.
Read More
Relevance: Medium-High
Strength of Science: High
Research Timeline: Post Approval
Guideline : Guidelines on exercise, diet, and weight during cancer treatment
Relevance: Medium-High
Strength of Science: High
Research Timeline: Post Approval
Most relevant for: People currently undergoing treatment for cancer
Most professional guidelines on exercise, diet and weight management have focused on the health of the general population and cancer survivors. The American Society of Clinical Oncology (ASCO) has now published evidence-based recommendations for exercise, diet and weight specifically for people who are in active treatment for cancer. (Posted 11/29/22) Este artículo está disponible en español.
Read More